Bagsværd, Denmark -14 September 2026: The Novo Nordisk rebrand officially launched, as the company unveiled a new brand platform centred on the phrase “Lasting Health Starts Now,” alongside a shift to the single “Novo” name for day-to-day use. Alongside the visual overhaul, the company introduced an updated corporate culture framework called “The Novo Way,” which is intended to help the organization move with greater focus, speed and impact as it enters what it describes as its next chapter.
The announcement was distributed through the company’s official newsroom and syndicated via GlobeNewswire on the morning of 14 September 2026. Novo Nordisk A/S remains the legal global company name, but “Novo” will now be used as the operating brand across markets, products, partnerships and stakeholder communications.
The Novo Nordisk rebrand was announced under the leadership of Mike Doustdar, president and CEO of Novo, who framed the change as a response to shifting patient expectations rather than a departure from the company’s scientific mission. He said people’s expectations of healthcare are changing, and that the company’s offerings must become more responsive, relevant and easier to fit into daily life. Doustdar added that the brand and culture updates are strategically important to how the company operates and competes, even as its underlying purpose remains unchanged.
Novo Nordisk Rebrand Introduces New Visual Identity and ‘Lasting Health Starts Now’ Platform
At the centre of the Novo Nordisk rebrand is the “Lasting Health Starts Now” platform, built on the premise that durable health outcomes begin with progress people can see and feel day by day, rather than at some undefined point in the future. According to the announcement, the platform is designed to give the company a more distinctive, recognisable and consistent way of engaging with patients, healthcare partners, investors and other stakeholders across global markets.
The updated visual identity retains the Apis bull logo, a symbol rooted in the company’s heritage, while presenting it in what the company describes as a more contemporary and future-fit expression. The rebrand does not change the company’s underlying legal structure: Novo Nordisk A/S continues to be the registered legal entity, while “Novo” becomes the public-facing name used across marketing, products and day-to-day operations globally.
The company frames the timing of the rebrand as tied to its broader ambition to bring breakthrough science closer to everyday life, particularly in the chronic disease categories, obesity and diabetes, where it says it has already transformed care for millions of patients. Novo Nordisk stated that despite this progress, unmet medical need in these areas remains substantial, which the company cites as a driver behind the strategic reset embodied in the rebrand.
‘The Novo Way’ Culture Framework Anchors the Novo Nordisk Rebrand
Introduced alongside the visual relaunch, “The Novo Way” is a new set of cultural principles intended to guide employee behaviour and internal decision-making. The company says the framework builds on strengths it associates with more than a century of operating history: breakthrough science, deep therapeutic expertise, care for patients, and a stated commitment to patient safety. At the same time, the framework is designed to instill behaviours suited to a faster-moving, more competitive and increasingly consumer-driven healthcare market.
The Novo Way is structured around four stated principles: Customer Obsession, which centres innovation on consumers and patients; Competitiveness, aimed at raising performance to create stakeholder value; Clarity, intended to sharpen focus and speed through simplified priorities and decisive action; and Care & Integrity, which the company says reflects its commitment to employee wellbeing, respect and uncompromising patient safety and ethics standards.
Tania Sabroe, executive vice president for People, Organisation & Corporate Affairs at Novo, said brand and culture work in tandem: culture shapes how the company executes its strategy and operates internally, while brand shapes how its products and services are perceived externally. Sabroe said the updated culture is meant to help the organization move with focus and speed, while the rebrand is meant to ensure relevance and distinctiveness across medicines, partnerships, marketing and stakeholder engagement.
The table below summarizes the four principles underpinning the culture side of the Novo Nordisk rebrand, as stated in the announcement.
| The Novo Way-Four Core Principles | Stated Purpose |
|---|---|
| Customer Obsession | Innovate with consumers and patients at the centre of everything the company does |
| Competitiveness | Raise performance to create greater value for all stakeholders |
| Clarity | Create focus and speed through clear priorities, simple ways of working and decisive action |
| Care & Integrity | Care for people, show respect, and maintain commitment to patient safety and ethics |
Leadership Reaction to the Novo Nordisk Rebrand Ahead of Capital Markets Day
Executive commentary accompanying the Novo Nordisk rebrand emphasized continuity of purpose alongside operational change. Doustdar’s remarks framed the rebrand and The Novo Way as connected components of how the company intends to deliver on its business objectives, describing the company’s broader ambition as bringing better health to many more people. He characterized the company’s founding purpose is changing people’s lives as unchanged, even as the brand and culture evolve.
Sabroe’s comments on the Novo Nordisk rebrand positioned the rebrand and culture update as mutually reinforcing levers meant to sharpen the company’s competitive position and strengthen its standing as a healthcare partner. Neither executive’s statement disclosed specific financial figures, budget allocations, or implementation timelines tied to the rebrand rollout; the company did not disclose the cost of the rebranding initiative, headcount changes associated with the transition, or country-by-country rollout schedules in the announcement reviewed for this article.
The company noted that further detail on its updated corporate strategy will be presented at its Capital Markets Day, scheduled for 21 September 2026 in London. Additional information on that event was directed to the Investor Relations section of the company’s website, though specific agenda items for the Capital Markets Day were not disclosed in the 14 September announcement.
The key facts of the Novo Nordisk rebrand announcement are summarized below.
| Rebrand Announcement-Key Facts | Detail |
|---|---|
| Announcement date | 14 September 2026 |
| Location | Bagsværd, Denmark |
| New brand platform | “Lasting Health Starts Now” |
| Operating name | “Novo” (legal name remains Novo Nordisk A/S) |
| Culture framework | “The Novo Way” |
| Visual identity element | Apis bull logo (retained, modernised) |
| Related investor event | Capital Markets Day, 21 September 2026, London |
What the Novo Nordisk Rebrand Signals for the Company’s Strategic Direction
The Novo Nordisk rebrand arrives as the company positions itself for its next chapter in a healthcare market it describes as increasingly consumer-driven and competitive. The announcement ties the rebrand explicitly to the company’s stated ambition of bringing better health to more people, framing both the new brand platform and The Novo Way as mechanisms for executing that ambition rather than standalone marketing exercises.
Per the company’s standard forward-looking disclosure practice, statements in the announcement regarding the company’s future direction, strategic priorities and business objectives should be read as forward-looking and subject to the risks and uncertainties the company outlines in its regulatory filings. The announcement itself did not include updated financial guidance, and any strategic or financial targets tied to the rebrand were not disclosed pending the Capital Markets Day presentation.
Novo describes itself in the announcement as a global healthcare company with more than a century of operating history, combining scientific expertise with an understanding of patients’ daily lives. The company states that more than 67,000 employees worldwide work to advance its purpose, and that it pursues partnerships, programmes and investments aimed at disease prevention, expanded treatment access and reduced environmental impact. These figures were presented by the company as current at the time of the announcement and were not independently verified beyond the source release.
| Company Snapshot (as stated in the announcement) | Detail |
|---|---|
| Employees worldwide | More than 67,000 |
| Operating history | Over 100 years |
| Core disease areas referenced | Obesity, diabetes |
| Legal entity name | Novo Nordisk A/S |
| Public-facing brand name | Novo |
| Headquarters | Bagsværd, Denmark |
| Media and Investor Contacts (Novo Nordisk) | Region |
|---|---|
| Ambre James-Brown | Global Media |
| Liz Skrbkova | US Media Relations |
| Michael Novod | Investors |
| Sina Meyer | Investors |
| Christoffer Togo Solgaard-Tullin | Investors |
| Ida Schaap Melvold | Investors |
| Mads Berner Bruun | Investors |
| Frederik Taylor Pitter | US Investors |
| Alex Bruce | US Investors |
The Novo Nordisk rebrand does not, according to the announcement, change the company’s product portfolio, regulatory status of its medicines, or the legal name under which it is registered with regulators and stock exchanges. Patients and healthcare professionals seeking information on specific products were directed by the company to its existing product listing page rather than to any new destination created for the rebrand. Investors following the transition are likely to look for further detail at the 21 September Capital Markets Day, where the company has indicated it will provide a fuller overview of its updated corporate strategy.
